ARTV
Artiva Biotherapeutics, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- May 19 ▲ Artiva Biotherapeutics announced five data presentations at the EULA…
- Jun 8 FDA: Artiva Biotherapeutics Highlights AlloNK® Data Presented a…
- Jul 21 to Jul 31 ▲ 6 days of insider buys: $3.5M by 1 insider, avg $9.82
- Aug 15 ▲ A strong institutional cluster formed in ARTV during 2026-Q2, with 6…
- Aug 18 ▼ 1 insider sell $5.1K at $12.00
- Aug 27 to Sep 8 ▼ 3 days of insider sells: $1.3M by 4 insiders, avg $11.17
- Oct 5 to Oct 6 ▼ 2 days of insider sells: $726.1K by 4 insiders, avg $6.92
- Oct 27 ▼ Artiva Biotherapeutics is discontinuing all development of its sole…
- Oct 29 ▼ Jefferies downgrades
- Nov 2 ▼ 4 insiders sell $343.5K at $4.18
- Nov 3 ▼ CEO and CMO sold shares days after the company discontinued its sole…
- Nov 9 ▼ Artiva Biotherapeutics filed an amended 8-K providing cost estimates…
Signal stack
Where each data set points today.
- InsidersMIXED
1 insider bought $3.5M at an average $9.82. 4 insiders sold $2.3M. Price is 59% below their cost.
- InstitutionsBULLISH
Q3 2026: 17 added (0 new), 6 trimmed or exited.
- AnalystsBULLISH
7 of 12 rate it Buy or better. Median target $19.50 (+386%).
- EstimatesFALLING
Current-quarter EPS estimate −$0.522 → −$0.534 over 90 days.
- Short sellersSTEADY
Short interest +7.9% to 2.95M shares. 1.8 days to cover, ≈6.0% of shares.
- TrendDOWNTREND
40% below its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| BlackRock, Inc. | DOUBLED | $10.8M |
| GEODE CAPITAL MANAGEMENT, LLC | ADD | $3.8M |
| STATE STREET CORP | DOUBLED | $2.4M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | DOUBLED | $1.8M |
| UBS Group AG | TRIM | $736.5K |
| Squarepoint Ops LLC | DOUBLED | $531.7K |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | $527.4K |
| MORGAN STANLEY | DOUBLED | $289.0K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
12 analystsPrice is inside the target range. Median implies +386%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Oct 29, 2026 | Jefferies DOWNGRADE | Hold |
| Oct 27, 2026 | Needham DOWNGRADE | Hold |
| Oct 27, 2026 | Wedbush DOWNGRADE | Neutral |
| Oct 2, 2026 | Cantor Fitzgerald REITERATE | Overweight |
| Jun 8, 2026 | Needham REITERATE | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Banerjee Subhashis Chief Medical Officer Nov 2, 2026 | SELL | $4.6K |
Aslan Fred Chief Executive Officer Nov 2, 2026 | SELL | $260.0K |
Horan Christopher Chief Tech Operations Officer Nov 2, 2026 | SELL | $43.6K |
Bush Jennifer COO, CLO, Compliance Officer Nov 2, 2026 | SELL | $35.3K |
Aslan Fred Chief Executive Officer Oct 6, 2026 | SELL | $168.9K |
Horan Christopher Chief Tech Operations Officer Oct 5, 2026 | SELL | $70.7K |
Banerjee Subhashis Chief Medical Officer Oct 5, 2026 | SELL | $7.5K |
Bush Jennifer COO, CLO, Compliance Officer Oct 5, 2026 | SELL | $57.2K |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.53 | -$0.56–-$0.47 | +0.0% | $0.00 |
| Next Q | -$0.17 | -$0.20–-$0.13 | +71.3% | $0.00 |
| Current FY | -$2.71 | -$3.01–-$2.30 | -7.8% | $0.00 |
| Next FY | -$1.53 | -$3.31–-$0.19 | +41.2% | $0.00 |
Short side
FINRA· Oct 30, 2026| Oct 27, 2026 | Resumption Scheduled | Resumed |
SecBot reports
28 filings · 5 press releases · 10 bullish · 7 bearish · 11 neutral- BEARISH 8-K/ANov 9, 2026
Artiva Biotherapeutics filed an amended 8-K providing cost estimates for its wind-down, which…
The company is effectively ceasing operations as a going concern with a 94% workforce reduction and no remaining pipeline disclosed. The strategic alternatives process will determine whether the…
- BEARISH CLUSTERNov 3, 2026
CEO and CMO sold shares days after the company discontinued its sole pipeline candidate, announced…
The CEO's unplanned open-market sale immediately after a clinical failure and restructuring signals insider belief that the strategic alternatives process may not yield a favorable outcome for…
- BEARISH 8-KOct 27, 2026
Artiva Biotherapeutics is discontinuing all development of its sole pipeline candidate AlloNK…
The company is now a cash-rich shell with no pipeline, a 94% workforce reduction, and a formal strategic alternatives process underway. The outcome of this process (liquidation, sale, or merger)…
- NEUTRAL 144Oct 6, 2026
Fred Aslan, a Director and Officer of Artiva Biotherapeutics, filed a Form 144 notice of intent to…
The proposed sale is small and routine for an insider with RSU vesting. Monitor for actual sale execution on Form 4, but no immediate catalyst. The 10b5-1 plan suggests the sale is pre-planned and…
All ARTV filing & press-release reports (33)
- 8-K/A reportNov 9, 2026
- CLUSTER reportNov 3, 2026
- 8-K reportOct 27, 2026
- 144 reportOct 6, 2026
- CLUSTER reportSep 9, 2026
- CLUSTER reportSep 9, 2026
- CLUSTER reportSep 9, 2026
- CLUSTER reportSep 9, 2026
- 8-K reportSep 11, 2026
- CLUSTER reportSep 9, 2026
- CLUSTER reportSep 4, 2026
- CLUSTER reportSep 4, 2026
- INST-CLUSTER reportAug 15, 2026
- INSIDER-BUY reportJul 31, 2026
- INSIDER-BUY reportJul 28, 2026
- INSIDER-BUY reportJul 23, 2026
- INSIDER-BUY reportJul 20, 2026
- INSIDER-BUY reportJul 14, 2026
- INSIDER-BUY reportJun 29, 2026
- INSIDER-BUY reportJun 16, 2026
- PRESS-RELEASE reportJun 8, 2026
- CLUSTER reportMay 19, 2026
- PRESS-RELEASE reportMay 19, 2026
- 8-K reportMay 19, 2026
- PRESS-RELEASE reportMay 19, 2026
- 144 reportMay 18, 2026
- 144 reportMay 18, 2026
- 8-K reportMay 8, 2026
- 8-K reportMay 8, 2026
- PRESS-RELEASE reportMay 8, 2026
- PRESS-RELEASE reportMay 8, 2026
- PRESS-RELEASE reportMar 10, 2026
- 8-K, 8-K reportFeb 24, 2026